Neil Jenkins

My practice is focused on litigating patents especially patents protecting pharmaceutical products in the UK as well as advising on and co-ordinating European patent litigation strategies more broadly.

I joined the London office of Bird & Bird in 1986 and became a partner in the Intellectual Property Group ten years later in 1996. I offer expertise in UK patent actions and the co-ordination of cross border patent litigation, in particular in the area of pharmaceuticals and medical devices. My practice also encompasses regulatory data exclusivity and supplementary protection certificates.

I speak at IP conferences and contribute to leading IP journals on aspects of IP law and litigation. I am also the editor of International Intellectual Property Litigation, published by Butterworths.

• I have recently run a pharmaceutical (MAb) patent case through to a successful first instance decision and a medical device case through to a successful settlement immediately before trial.

• All reported (first and/or second instance):
• Takeda v Roche (MAb)
• Rhodia v Molycorp (Cerium oxide catalyst)
• Synthon v Teva (GA process)
• Novartis v Teva (Rivastigmine)
• Generics v Teva (GA)
• Teva v Merck (Timolol/Dorzolamide combination)
• Actavis v Novartis (Fluvastatin)
• Actavis v Merck (Finasteride)
• Abbot v APS (Clarithromycin)
• Lundbeck v Niche (Citalopram)
• Teva v Merck (Simvastatin)
• Teva v Merck (Alendronate)
• Agilent v Waters (HPLC pump)
• Hesco v Maccaferri (Gabion)
• Stephenson v Du Pont (Kevlar composite)
• UCC v BP (Fluid bed)
• HCC v BP (Acetyl purification)
• ICI v Montedison (Polymer composite)
• PLG v Ardon (Plastic netting)